PJ34 inhibition across PARP-family enzyme constructs
Biochemical assay · Purified human PARP-family full-length enzymes and catalytic-domain constructs listed in Table 2 [1]
A single comparative enzyme-profiling design supports broad PARP-family inhibition. Potency varies by enzyme and construct; weaker PARP10/14/15 responses are retained. Individual enzyme rows are endpoints of this study, not separate studies.
| Endpoint | Reported result | Reference |
|---|---|---|
| Full-length PARP1 ADP-ribosylation inhibition | IC50; pIC50 10.9 nM; pIC50 7.96 ± 0.10 | [1] |
| PARP1 ART fragment ADP-ribosylation inhibition | IC50; pIC50 61 nM; pIC50 7.22 ± 0.13 | [1] |
| Full-length PARP2 ADP-ribosylation inhibition | IC50; pIC50 33.5 nM; pIC50 7.48 ± 0.06 | [1] |
| PARP2 ART fragment ADP-ribosylation inhibition | IC50; pIC50 382 nM; pIC50 6.42 ± 0.06 | [1] |
| Full-length PARP3 ADP-ribosylation inhibition | IC50; pIC50 1430 nM; pIC50 5.84 ± 0.15 | [1] |
| TNKS1 ART fragment ADP-ribosylation inhibition | IC50; pIC50 1690 nM; pIC50 5.77 ± 0.05 | [1] |
| TNKS2 ART fragment ADP-ribosylation inhibition | IC50; pIC50 2900 nM; pIC50 5.53 ± 0.10 | [1] |
| Full-length PARP10 ADP-ribosylation inhibition | IC50; pIC50 5800 nM; pIC50 5.23 ± 0.10 | [1] |
| PARP10 ART fragment ADP-ribosylation inhibition | IC50; pIC50 6800 nM; pIC50 5.17 ± 0.15 | [1] |
| PARP12 ART fragment ADP-ribosylation inhibition | IC50; pIC50 230 nM; pIC50 6.65 ± 0.11 | [1] |
| PARP14 ART fragment ADP-ribosylation inhibition | IC50; pIC50 4200 nM; pIC50 5.38 ± 0.05 | [1] |
| PARP15 ART fragment ADP-ribosylation inhibition | IC50; pIC50 9000 nM; pIC50 5.05 ± 0.15 | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response series; assay IC50 values are endpoints, not treatment recommendations.
- Exposure duration
- 15 min preincubation before NAD+ addition; reaction duration not specified in acquired main-text assay description.
- Method
- ADP-ribosylation assay with NAD+ at each construct’s KM or below; CLARIOstar reader.
- Vehicle
- 1% DMSO final; control reactions used DMSO from the same batch.
- Reported limits
- Detailed SI assay settings and material certificates were not retrieved. Per-enzyme repetition counts are not supplied in the acquired table: general methods report 2 or 3 technical replicate series and 1–5 repetitions.
Methods and source locations
Compound reported in the paper: PJ34; Compound label in the paper: PJ34
Literature results for the PJ34 parent compound as tested in solution; no validation of this free-base catalog lot, no salt conversion, and no assumption of formulation equivalence.
Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics
Full-length PARP1 ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; Full-length PARP1 row
PARP1 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP1 ART fragment row
Full-length PARP2 ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; Full-length PARP2 row
PARP2 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP2 ART fragment row
Full-length PARP3 ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; Full-length PARP3 row
TNKS1 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; TNKS1 ART fragment row
TNKS2 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; TNKS2 ART fragment row
Full-length PARP10 ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; Full-length PARP10 row
PARP10 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP10 ART fragment row
PARP12 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP12 ART fragment row
PARP14 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP14 ART fragment row
PARP15 ART fragment ADP-ribosylation inhibition: PARP automodification or histone modification; three-parameter curve fitting. pIC50 uncertainty is reported standard error of a representative experiment, not SD or IC50 uncertainty. — Table 2, PJ34 columns and footnote a; Experimental Sections: In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics; PARP15 ART fragment row